Compare Summit Therapeutics Inc (SMMT) vs Advanced Drainage Systems Inc (WMS) Price & Performance

Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.

The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.

Advanced Drainage Systems (WMS) trades at $126.21, up 0.1% with a bearish technical signal. The company shows strong profitability with 14% net margins and 24.9% ROE, though recent earnings beat expectations. Revenue remains stable around $2.9B with solid cash flow generation. Institutional activity shows mixed sentiment with major players like BlackRock increasing positions while others reduced stakes.

WMS presents a compelling value opportunity with analyst consensus target of $188.20 (49% upside) despite near-term technical weakness. Strong fundamentals and market leadership in water management support long-term growth, though investors face risks from cyclical construction demand and elevated valuation multiples relative to historical levels.